ArticleImmunity, inflammation and disease2026
An In Silico Omics Investigation of the Lactobacillus Genus Complex for Allergenicity Mitigation.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundAmong the useful methods of immune response modulation, probiotics can be included. A delicate balance in the microbiome is of extreme importance for immune homeostasis, the composition of which is influenced by lifestyle and dietary habits. The aim of this study was to identify Lactobacillus strains with potential allergenicity-mitigating properties through comprehensive in silico analysis of their genomes and proteomes. Abrogation in such a balance may lead to the development of food allergy. So far, certain components in probiotics, including immunosuppressive motifs or metabolites like 17,18-epoxy eicosatetraenoic acid (17,18 EpETE), seem to have the potential to reduce prevalence. However, some bacterial proteins may be allergenic or may induce cross-reactivity.
methodsWe performed an in silico study over the 161 reference genomes and proteomes of Lactobacillus. We analyzed the presence of Nucleotide immunosuppressive motifs (NISM)s, calculated the per million frequency of bases, and checked for the presence of the CYP450 enzymes/stable allergen epitopes. This was evaluated using various bioinformatics tools like Uniprot proteomes, NCBI genomes, AlgPred, PeptideCutter, EMBOSS, and MAST.
resultsOur analysis identified Latilactobacillus sakei as a promising candidate, based on its genomic and proteomic features, for mitigating allergenicity.
conclusionsLatilactobacillus sakei might be a useful candidate for nutritional allergy management and related conditions. However, this potential requires verification through further experimental studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.